Resistance Mechanisms to Anti-PD Cancer Immunotherapy.

Vesely, Matthew D; Zhang, Tianxiang; Chen, Lieping

Vesely, Matthew D; Zhang, Tianxiang; Chen, Lieping.

Affiliation

Vesely MD; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA; email: lieping.chen@yale.edu.
Zhang T; Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA.
Chen L; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA; email: lieping.chen@yale.edu.

Annu Rev Immunol ; 40: 45-74, 2022 04 26.

Article in En | MEDLINE | ID: mdl-35471840

Subject(s)

Neoplasms; Programmed Cell Death 1 Receptor; Animals; B7-H1 Antigen; Humans; Immunotherapy; Neoplasms/drug therapy; Neoplasms/metabolism; T-Lymphocytes; Tumor Microenvironment

Key words

PD-1/B7-H1; anti-PD-1/PD-L1 therapy; immunotherapy resistance; normalization cancer immunotherapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Programmed Cell Death 1 Receptor / Neoplasms Limits: Animals / Humans Language: En Journal: Annu Rev Immunol Year: 2022 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google